Regulus Therapeutics Inc.

University of Washington

The Brigham and Women's Hospital, Inc.

Cincinnati Children's Hospital Medical Center

Baxter International Inc.

Baxter Healthcare Sa

Jeremy Duffield

Balkrishen Bhat

Amy Cohen

David L Amrani

Deidre A MacKenna

Rashmi Hedge

Catherine M Hoff

Shuyu Ren

Richard A Lang

Delara Motlagh

Provided herein are methods for the treatment of Alport Syndrome, using modified oligonucleotides targeted to miR-21. In certain embodiments, a modified oligonucleotide targeted to miR-21 improves kidney function and/or reduces fibrosis in subjects having Alport Syndrome. In certain embodiments, administration of a modified oligonucleotide targeted to miR-21 delays the onset of end-stage renal disease in a subject having Alport Syndrome. In certain embodiments, a modified oligonucleotide targeted to miR-21 delays the need for dialysis or kidney transplant in a subject having Alport Syndrome.

Methods for treatment of alport syndrome

The present disclosure provides molecules, compositions and methods for treating scarring in organs. The molecules, compositions and methods treat scarring by modulating the WNT, platelet-derived growth factor receptor (PDGFR), transforming growth factor-beta (TGF3) and/or connective-tissue growth factor (CTGF) signaling pathways.

Administration of DKK1 muteins to treat fibrosis

Methods of treating solid organ injuries using compounds that enhance Wnt signalling are described.

Agents and methods for tissue repair and regeneration

Growing community of inventors

Seattle, WA, United States of America

Jeremy Duffield